GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A (different lots)
Biological: Infanrix hexa
Biological: Infanrix-IPV/Hib
Biological: Rotarix

First Posted Date: 2008-12-15

Last Posted Date: 2018-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 466

Registration Number: NCT00808444

Locations: 🇸🇬
GSK Investigational Site, Singapore, Singapore

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Biological: GSK Biologicals' Hepatitis B vaccines (GSK223192A)
Biological: Fendrix™
Biological: Engerix-B™
Biological: HBsAg (Booster injection)

First Posted Date: 2008-12-09

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 713

Registration Number: NCT00805389

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Phase 2

Completed

Conditions: Herpes Zoster

Interventions: Biological: Herpes zoster vaccine GSK1437173A
Biological: Placebo

First Posted Date: 2008-12-05

Last Posted Date: 2019-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 410

Registration Number: NCT00802464

Locations: 🇪🇸
GSK Investigational Site, Marid, Spain

A Healthy Volunteer Study With Inhaled GSK573719 and Placebo

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: 100mcg
Drug: Placebo
Drug: 500mcg
Drug: 1000mcg

First Posted Date: 2008-12-05

Last Posted Date: 2017-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00803673

Locations: 🇧🇪
GSK Investigational Site, Antwerpen, Belgium

Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)

Phase 4

Completed

Conditions: Leukaemia, Lymphocytic, Chronic

Interventions: Drug: Ofatumumab

First Posted Date: 2008-12-05

Last Posted Date: 2014-05-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 29

Registration Number: NCT00802737

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

Phase 3

Completed

Conditions: Atherosclerosis

Interventions: Drug: Darapladib
Drug: Placebo

First Posted Date: 2008-12-01

Last Posted Date: 2017-08-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15828

Registration Number: NCT00799903

Locations: 🇬🇧
GSK Investigational Site, Paisley, United Kingdom

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase 3

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: GSK Biological's HPV vaccine GSK580299 (Cervarix™)

First Posted Date: 2008-12-01

Last Posted Date: 2018-07-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 346

Registration Number: NCT00799825

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Phase 3

Terminated

Conditions: Melanoma

Interventions: Drug: Placebo
Drug: GSK 2132231A

First Posted Date: 2008-11-24

Last Posted Date: 2021-03-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1351

Registration Number: NCT00796445

Locations: 🇬🇧
GSK Investigational Site, Salisbury, United Kingdom

Relapse Prevention Study in Newly Abstinent Smokers

Phase 2

Withdrawn

Conditions: Substance Dependence

Interventions: Drug: GSK598809
Drug: Nicotine Replacement Transdermal Patch
Drug: Placebo

First Posted Date: 2008-11-19

Last Posted Date: 2016-02-15

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT00793468

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

Phase 2

Completed

Conditions: Varicella

Interventions: Biological: VarilrixTM

First Posted Date: 2008-11-18

Last Posted Date: 2018-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 45

Registration Number: NCT00792623

Locations: 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy